about
Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosisPaget disease of bone-associated UBA domain mutations of SQSTM1 exert distinct effects on protein structure and functionOspemifene use in postmenopausal women.Estrogen receptor gene polymorphisms and the genetics of osteoporosis: a HuGE review.ZNF687 Mutations in Severe Paget Disease of Bone Associated with Giant Cell Tumor.Update on the pharmacogenetics of the vitamin D receptor and osteoporosis.The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone.Perspectives in the treatment and prevention of osteoporosis.Aromatase activity and bone loss.Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis.Clinical characteristics and evolution of giant cell tumor occurring in Paget's disease of bone.Appropriate models for novel osteoporosis drug discovery and future perspectives.Treatment needs and current options for postmenopausal osteoporosis.A nonsynonymous TNFRSF11A variation increases NFκB activity and the severity of Paget's disease.Paget's disease of bone in Italy.Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis.Giant cell tumor occurring in familial Paget's disease of bone: report of clinical characteristics and linkage analysis of a large pedigree.Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men.A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism.Vitamin D receptor gene polymorphisms predict acquired resistance to clodronate treatment in patients with Paget's disease of bone.The effects of zoledronic acid on serum lipids in multiple myeloma patients.The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels.Hypovitaminosis D and organ damage in patients with arterial hypertension: a multicenter double blind randomised controlled trial of cholecalciferol supplementation (HYPODD) : study design, clinical procedures and treatment protocol.Common susceptibility alleles and SQSTM1 mutations predict disease extent and severity in a multinational study of patients with Paget's disease.Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone.Evidence for increased clinical severity of familial and sporadic Paget's disease of bone in Campania, southern ItalySerum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of boneComparison of different intravenous bisphosphonate regimens for Paget's disease of boneQuantitative ultrasound and dual-energy X-ray absorptiometry in the prediction of fragility fracture in menRaloxifene in breast cancer preventionSQSTM1 gene analysis and gene-environment interaction in Paget's disease of boneCirculating sclerostin levels and bone turnover in type 1 and type 2 diabetesFSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal womenThe association of body composition and sex hormones with quantitative ultrasound parameters at the calcaneus and phalanxes in elderly womenPaget's Disease of Bone
P50
Q28258418-B12F3948-E6AC-4A25-8E79-E90E11F9B60DQ30360327-0303A5A2-C26B-422B-AD7A-427CF47088FCQ34982860-DE7782A2-E7B9-46C8-B424-44FF7BE84D9FQ36030305-CC37605F-1BF1-4784-BD68-0DC5775FD872Q36559236-B7A23A50-3616-47AA-9235-BC97CD4DBFB0Q37416122-5001D172-2FAC-4C22-A90F-BE815DB93609Q37581904-5E0BF8C1-3B0A-461F-948D-2F198E4B3437Q37635782-6D9C8B97-B00F-4D0A-9B5A-7FE3B479CD36Q37923425-861B3777-8EDD-4F3D-8997-A6E4E8C4C150Q37987236-74A6145A-4C8E-4877-B80D-123CF33DA4BDQ38246759-0FE809BD-276D-4FB2-A49F-504C4CB235A4Q38570326-AB89A252-E79C-4F4C-A3F7-C16102980E3DQ38800928-19377F2A-5863-4283-92CA-5BCF707D6707Q39460310-0108BD75-D02E-4F82-BDE1-3D76982D4C6DQ39782394-8D383694-8467-4DA2-934D-C0C689BEFEDEQ39788803-17100A80-D87D-43BA-8249-9784C7201520Q44613189-06B73D7E-428F-472E-A251-487FD7FA32F7Q44645555-33C5A680-628D-4AB9-8C1B-5E2FD7E84770Q44924325-F505D95F-6CBA-4E6E-924D-037AECB94FF0Q46236942-47982306-589D-41AE-ABBA-85B3E8C9ADBCQ46640199-9833D589-1CEA-4AF2-8A17-737EDF9B6C3AQ46655003-B407F5BF-AB06-4342-8E84-61454A1C8B79Q49141329-69DE3066-666D-4381-BA6B-2D61E910CAC3Q51009002-C1F5E4F4-6869-48ED-A581-0E95E001E112Q53064404-95AC93C9-C911-4792-9A9A-10065029C98FQ79141868-FD441057-68CE-4F5C-81A1-6D9DE85F1F73Q80273977-CCFB0A30-2871-4A38-815E-BBE1C8CA2EC4Q80555576-329C9120-FE53-4A2A-8AF7-7CCFA1CD8487Q81145920-564980DE-ED25-40E6-AD49-D072D7DF6FECQ81230512-1DD0AFCF-8D8B-4C8C-B36A-FB0359E1C8BEQ83122853-A6C13D67-D37B-45DC-A552-B451D93986E2Q83594313-E96ED6DD-FDE1-4D92-B812-E15D6459F975Q83900950-0BC4E459-A93E-428B-8C1A-63B8A1D581ABQ85071297-894294C9-3C12-4143-8352-B48280844CF4Q91172023-596E9F9A-1127-43A9-9CB3-41E53149E49B
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Daniela Merlotti
@ast
Daniela Merlotti
@en
Daniela Merlotti
@es
Daniela Merlotti
@nl
Daniela Merlotti
@sl
type
label
Daniela Merlotti
@ast
Daniela Merlotti
@en
Daniela Merlotti
@es
Daniela Merlotti
@nl
Daniela Merlotti
@sl
prefLabel
Daniela Merlotti
@ast
Daniela Merlotti
@en
Daniela Merlotti
@es
Daniela Merlotti
@nl
Daniela Merlotti
@sl
P214
P106
P1153
6505831537
P21
P214
P31
P396
IT\ICCU\BVEV\193302
P496
0000-0002-3338-6339
P569
1975-01-01T00:00:00Z
P735
P7859
viaf-307327098